Nepafenac (1) – Nevanac®
Postoperative pain after eye surgery
Characteristics
| Start date | 01.07.2013 – Marketing authorisation: 11.12.2007 |
|---|---|
| Resolution | 19.12.2013 |
| INN | Nepafenac |
| Brand name | Nevanac® |
| Pharm. company | Alcon Pharma GmbH |
| G-BA Procedure ID | D-070 |
| ATC code | S01BC10 Antiinflammatory agents, non-steroids (S01BC) |
| DDD | 0.15 mg eye drops |
| Therapeutic area | Eye diseases |
| Reason for procedure | Initial assessment |
Studies and Results
a) Patients for the prevention and treatment of post-operative pain and inflammation following cataract surgery
- As the necessary evidence has not been provided in full, the additional benefit in relation to the appropriate comparator therapy is deemed not proven (Section 35a(1), fifth sentence, of Book V of the Social Code [SGB V]).
b) Patients for the reduction of the risk of post-operative macular oedema associated with cataract surgery in diabetic patients
- As the necessary evidence has not been submitted in full, the additional benefit in relation to the appropriate comparator therapy is deemed not proven (Section 35a(1), fifth sentence, SGB V).
Courtesy translation only, please refer to the German original.
Associated procedures
| Nepafenac (1) | Nevanac® | Alcon Pharma GmbH | Postoperative pain after eye surgery | 850,000–1,000,000 | 100% additional benefit not proven |
<< List of all resolutions